Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope‐specific IgE antibody profiling

Background IgE‐epitope profiling can accurately diagnose clinical peanut allergy. Objective We sought to determine whether sequential (linear) epitope‐specific IgE (ses‐IgE) profiling can provide probabilities of tolerating discrete doses of peanut protein in allergic subjects undergoing double‐blind, placebo‐controlled food challenges utilizing PRACTALL dosing. Methods Sixty four ses‐IgE antibodies were quantified in blood samples using a bead‐based epitope assay. A pair of ses‐IgEs that predicts Cumulative Tolerated Dose (CTD) was determined using regression in 75 subjects from the discovery cohort. This epitope‐based predictor was validated on 331 subjects from five independent cohorts (ages 4–25 years). Subjects were grouped based on their predicted values and probabilities of reactions at each CTD threshold were calculated. Results In discovery, an algorithm using two ses‐IgE antibodies was correlated with CTDs (rho = 0.61, p